This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnson, K. H. Articles by Westermark, P. Search for Related Content PubMed PubMed Citation Articles by Johnson, K. H. Articles by Westermark, P.

American Journal of Pathology, Vol 135, 245-250, Copyright © 1989 by American Society for Investigative Pathology

REGULAR ARTICLES

Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells

KH Johnson, TD O'Brien, K Jordan and P Westermark
Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Minnesota, St. Paul 55108.

Adult cats determined by clinical laboratory evaluations to be normal, impaired glucose tolerant, or overtly diabetic were used to explore prospectively the relationships among pancreatic beta cell islet amyloid polypeptide (IAPP) immunoreactivity, islet amyloid (IA) deposition, and diabetogenesis. IAPP-derived IA was found in 11 of 14 (79%) diabetic cats, in four of nine (44%) impaired glucose tolerant cats, and in two of eight (25%) normal adult cats. The presence of IA even in very small amounts, therefore, predicts a very high probability (88%) that an animal has either impaired glucose tolerance or overt DM. Although all overtly diabetic cats had a marked decrease or absence of beta cell IAPP immunoreactivity, six of six cats with impaired glucose tolerance retained IAPP immunoreactivity with 1:15,000 dilutions of antisynthetic IAPP 7-17, whereas only one of seven normal cats had IAPP immunoreactivity beyond 1:10,000 dilutions. These findings suggest that increased IAPP production preceding the development of overt DM is linked to the progressive formation of insoluble IA deposits that are apparent in most overtly diabetic individuals. Of most importance, in that IAPP has been reported to inhibit both basal and insulin- stimulated rates of glycogen synthesis, is the possibility that increased production and release of IAPP by pancreatic beta cells plays a key role in the development of the insulin resistance and impaired glucose tolerance, both of which occur in Type 2 DM.

This article has been cited by other articles:

				W. P.S. Wong, D. W. Scott, C.-L. Chuang, S. Zhang, H. Liu, A. Ferreira, E. L. Saafi, Y. S. Choong, and G. J.S. Cooper Spontaneous Diabetes in Hemizygous Human Amylin Transgenic Mice That Developed Neither Islet Amyloid nor Peripheral Insulin Resistance Diabetes, October 1, 2008; 57(10): 2737 - 2744. [Abstract] [Full Text] [PDF]

				K. Iki and P. M. Pour Distribution of Pancreatic Endocrine Cells Including IAPP-expressing Cells in Non-diabetic and Type 2 Diabetic Cases J. Histochem. Cytochem., February 1, 2007; 55(2): 111 - 118. [Abstract] [Full Text] [PDF]

				R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3629 - 3643. [Abstract] [Full Text] [PDF]

				F. Wang, R. L. Hull, J. Vidal, M. Cnop, and S. E. Kahn Islet Amyloid Develops Diffusely Throughout the Pancreas Before Becoming Severe and Replacing Endocrine Cells Diabetes, November 1, 2001; 50(11): 2514 - 2520. [Abstract] [Full Text] [PDF]

				M. Hoenig, G. Hall, D. Ferguson, K. Jordan, M. Henson, K. Johnson, and T. O'Brien A Feline Model of Experimentally Induced Islet Amyloidosis Am. J. Pathol., December 1, 2000; 157(6): 2143 - 2150. [Abstract] [Full Text] [PDF]

				J. Permert, J. Larsson, G. T. Westermark, M. K. Herrington, L. Christmanson, P. M. Pour, P. Westermark, and T. E. Adrian Islet Amyloid Polypeptide in Patients with Pancreatic Cancer and Diabetes N. Engl. J. Med., February 3, 1994; 330(5): 313 - 318. [Abstract] [Full Text]